Alerian MLP Index ETNs due January 28 2044 financials
$35.22−0.42%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $280.35B | $278.91B |
| Gross profit | $182.45B | $177.56B |
| Gross margin | 65.1% | 63.7% |
| Operating income | $72.59B | $75.08B |
| Net income | $55.68B | $56.87B |
| Net margin | 19.9% | 20.4% |
| Diluted EPS | $20.02 | $19.75 |
| EBITDA | $72.59B | $75.08B |
| Operating cash flow | -$147.78B | -$42.01B |
| Free cash flow | -$147.78B | -$42.01B |
| Diluted shares | 2,781.5M | 2,879.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $21.74B | $23.37B |
| Short-term investments | $2.52T | $2.28T |
| Total debt | $499.98B | $454.31B |
| Total assets | $4.42T | $4.00T |
| Total liabilities | $4.06T | $3.66T |
| Shareholders' equity | $362.44B | $344.76B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology